Drug Profile
SIB 1663
Alternative Names: S 1663; SIB S1663Latest Information Update: 12 Feb 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease; Schizophrenia
Most Recent Events
- 05 Oct 1998 No-Development-Reported for Parkinson's disease in USA (Unknown route)
- 05 Oct 1998 No-Development-Reported for Schizophrenia in USA (Unknown route)
- 12 Sep 1996 Preclinical development for Schizophrenia in USA (Unknown route)